Fibrobiologics Inc (FBLG) Stock Price, Quote & News

Company Profile

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company was founded in 2021 and is based in Houston, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 281-651-5150

Website: www.fibrobiologics.com

Address:

455 East Medical Center Boulevard, Suite 300, Houston, United States

123MONEYGUY Dec. 26 at 9:05 PM

$FBLG buy alert ⚠️ 📢 👀 😳 😍 😎 ⚠️ 📢 👀 😳

0 · Reply

Enoch120 Dec. 26 at 4:38 PM

$FBLG hoping retail pushes this over $1.

0 · Reply

Enoch120 Dec. 26 at 4:25 PM

$FBLG It appears institutions will not be buyers until this price is well above $1 p/s, it’s amazing they own about 10%. I don’t know if retail has enough staying power to get the price over $1. I don’t like reverse splits but this potential is too fascinating to ignore..

0 · Reply

GreenWashingG Dec. 25 at 11:14 AM

$FBLG Forward risk‑reward now depends less on headlines and more on execution depth across functions. Progress needs to be observable in both leading indicators and reported metrics. Aligned incentives and governance can stabilize expectations. Overall, the trajectory is less about vision and more about proving the operating model works.

0 · Reply

profitmaker007 Dec. 24 at 7:37 AM

$FBLG seems a good investment for 2026 🤔

1 · Reply

vinkush1 Dec. 17 at 6:10 PM

$FBLG R/S soon 🥲

1 · Reply

MisoHawny Dec. 17 at 3:34 PM

$FBLG hopefully the worst is behind us now that it has reclaimed 24.

1 · Reply

Evilalchemist Dec. 15 at 4:30 PM

$FBLG here we go

0 · Reply

Evilalchemist Dec. 15 at 4:29 PM

$FBLG 1.7 million direct offering approved

0 · Reply

stockanalysis_ Dec. 15 at 2:54 PM

Losers Today: $IRBT $CCHH $FBLG $ASNS $LEXX Save this screener: https://stockanalysis.com/markets/losers/?ref=saveontrading

0 · Reply

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 12 days ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 10, 2025, 11:36 AM EST - 17 days ago

FibroBiologics Files New Patent For Fibroblast Tech To Advance Deeper Into Orthopedics

Dec 10, 2025, 8:30 AM EST - 17 days ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Nov 26, 2025, 8:30 AM EST - 4 weeks ago

FibroBiologics Announces Payoff of Outstanding Debt

Nov 25, 2025, 4:05 PM EST - 4 weeks ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 4 weeks ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers$

Nov 20, 2025, 8:00 AM EST - 5 weeks ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 19, 2025, 7:03 PM EST - 5 weeks ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 5 weeks ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 31, 2025, 4:30 PM EDT - 2 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 24, 2025, 8:30 AM EDT - 2 months ago

FibroBiologics to Present at Bio-Europe 2025

Oct 14, 2025, 8:30 AM EDT - 2 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

Sep 23, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

Sep 12, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies

Sep 11, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment

Sep 10, 2025, 8:30 AM EDT - 3 months ago

FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies

Aug 27, 2025, 8:30 AM EDT - 4 months ago

FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 31, 2025, 4:30 PM EDT - 5 months ago

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 28, 2025, 8:30 AM EDT - 5 months ago

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Jul 11, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics to Present at the Advanced Wound Care Summit USA

Jul 9, 2025, 8:30 AM EDT - 6 months ago

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank

Jul 7, 2025, 4:35 PM EDT - 6 months ago

FibroBiologics' to Present at Exclusive Live Investor Webinar and Q&A Session on July 10

Jun 16, 2025, 4:35 PM EDT - 6 months ago

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

Jun 16, 2025, 9:50 AM EDT - 6 months ago

FibroBiologics to Present at the BIO International Convention 2025

Jun 9, 2025, 8:30 AM EDT - 7 months ago

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

May 16, 2025, 8:30 AM EDT - 8 months ago

FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting

May 14, 2025, 4:30 PM EDT - 8 months ago

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 9:15 AM EDT - 8 months ago

FibroBiologics Presenting at the ThymUS 2025 Meeting

Apr 29, 2025, 9:15 AM EDT - 8 months ago

FibroBiologics Presents at the ThymUS 2025 Meeting

Apr 11, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Apr 8, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics

Apr 2, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair

Mar 31, 2025, 4:25 PM EDT - 9 months ago

FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 8:30 AM EDT - 9 months ago

FibroBiologics Announces 2025 Annual Meeting of Stockholders

Mar 21, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting

Mar 4, 2025, 8:30 AM EST - 10 months ago

FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics

Feb 27, 2025, 8:30 AM EST - 10 months ago

FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic

Feb 5, 2025, 9:15 AM EST - 11 months ago

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

Dec 30, 2024, 4:30 PM EST - 1 year ago

FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing

Dec 30, 2024, 2:12 PM EST - 1 year ago

D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing

Dec 23, 2024, 7:55 AM EST - 1 year ago

FibroBiologics Announces $25 Million Financing

Nov 19, 2024, 9:15 AM EST - 1 year ago

FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly

Nov 14, 2024, 9:15 AM EST - 1 year ago

FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics

Nov 12, 2024, 4:20 PM EST - 1 year ago

FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 29, 2024, 9:15 AM EDT - 1 year ago

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology

Oct 28, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024

Oct 18, 2024, 8:30 AM EDT - 1 year ago

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

Oct 16, 2024, 9:15 AM EDT - 1 year ago

FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office

Oct 11, 2024, 9:31 AM EDT - 1 year ago

FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit

123MONEYGUY Dec. 26 at 9:05 PM

$FBLG buy alert ⚠️ 📢 👀 😳 😍 😎 ⚠️ 📢 👀 😳

0 · Reply

Enoch120 Dec. 26 at 4:38 PM

$FBLG hoping retail pushes this over $1.

0 · Reply

Enoch120 Dec. 26 at 4:25 PM

0 · Reply

GreenWashingG Dec. 25 at 11:14 AM

0 · Reply

profitmaker007 Dec. 24 at 7:37 AM

$FBLG seems a good investment for 2026 🤔

1 · Reply

vinkush1 Dec. 17 at 6:10 PM

$FBLG R/S soon 🥲

1 · Reply

MisoHawny Dec. 17 at 3:34 PM

$FBLG hopefully the worst is behind us now that it has reclaimed 24.

1 · Reply

Evilalchemist Dec. 15 at 4:30 PM

$FBLG here we go

0 · Reply

Evilalchemist Dec. 15 at 4:29 PM

$FBLG 1.7 million direct offering approved

0 · Reply

stockanalysis_ Dec. 15 at 2:54 PM

Losers Today: $IRBT $CCHH $FBLG $ASNS $LEXX Save this screener: https://stockanalysis.com/markets/losers/?ref=saveontrading

0 · Reply

KardiTheViking Dec. 15 at 2:46 PM

$FBLG these guys are poorer than me 😂 what useless offering is that

0 · Reply

Moneywheel Dec. 15 at 2:07 PM

$FBLG on watch

0 · Reply

stockanalysis_ Dec. 15 at 2:01 PM

Premarket Losers: $IRBT $UCL $FBLG $CCHH $LEXX Bookmark this page: https://stockanalysis.com/markets/premarket/losers/?ref=saveontrading

0 · Reply

vinkush1 Dec. 15 at 1:18 PM

$FBLG such BS offering again

2 · Reply

McMillion1 Dec. 13 at 12:58 AM

$FBLG

0 · Reply

MisoHawny Dec. 12 at 5:22 PM

$FBLG there are a bunch of liquidity voids on the daily. Careful, it could retrace pretty hard before rising again.

2 · Reply

StockWriter69 Dec. 12 at 2:40 PM

$FBLG can someone explain it to me, why is this one so low?

1 · Reply

vinkush1 Dec. 12 at 2:38 PM

$FBLG INSIDER BUYING

0 · Reply

Target25UP Dec. 11 at 8:45 PM

$FBLG what u guys thinking for AH

0 · Reply

Cookem_up09 Dec. 11 at 5:59 PM

$FBLG

0 · Reply

KardiTheViking Dec. 11 at 4:51 PM

$FBLG who is so crazy to sell this beauty?? 💎😍

0 · Reply

MaskMaker Dec. 11 at 5:30 AM

$FBLG 618

1 · Reply

Market Cap	16.56M
Revenue (ttm)	0.00
Net Income (ttm)	-11.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	35.15

Volume	1,449,700
Avg Vol	1,502,348
Day's Range	N/A - N/A
Shares Out	66.52M
Stochastic %K	33%
Beta	-0.58
Analysts	Strong Sell
Price Target	$8.75